Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis

Yoon J, Chen CY, Watson R, Smyth E, Wainberg Z, Oh DY. Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. Am Soc[...]

Davenport S, Xie B, Hamblett K, Hausman D, Villalobos I, Singh HP, Cobrinik D, Hoon DSB, Zhou JY, Sibug-Saber M, Ma Y, Konecny GE, Heur[...]

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou[...]